Advanced search
Publication Cover
Emerging Microbes & Infections Volume 10, 2021 - Issue 1
Submit an article Journal homepage
38,843
Views
160
CrossRef citations to date
0
Altmetric
Coronaviruses

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

Kelvin Kai-Wang Toa State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;b Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;c Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;d Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1921-5824View further author information
ORCID Icon,
Siddharth Sridhara State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;b Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;c Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;d Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2022-8307View further author information
ORCID Icon,
Kelvin Hei-Yeung Chiud Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaView further author information
,
Derek Ling-Lung Hungd Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaView further author information
,
Xin Lid Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaView further author information
,
Ivan Fan-Ngai Hunge Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaView further author information
,
Anthony Raymond Tame Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaView further author information
,
Tom Wai-Hin Chungd Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaView further author information
,
Jasper Fuk-Woo Chana State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;b Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;c Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;d Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-6336-6657View further author information
ORCID Icon,
Anna Jian-Xia Zhanga State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;b Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;c Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-5087-3614View further author information
ORCID Icon,
Vincent Chi-Chung Chengd Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaView further author information
&
Kwok-Yung Yuena State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;b Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;c Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China;d Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2083-1552View further author information
ORCID Icon show all
Pages 507-535 | Received 07 Feb 2021, Accepted 28 Feb 2021, Published online: 22 Mar 2021

References

  • National Geographic. (2020). ‘Wet markets’ likely launched the coronavirus. Here’s what you need to know. https://www.nationalgeographic.com/animals/2020/04/coronavirus-linked-to-chinese-wet-markets/. Accessed 4 February.
  • Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2020;16:e1008536.
  • Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
  • Pekar J, Worobey M, Moshiri N, et al. Timing the SARS-CoV-2 index case in Hubei Province. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.11.20.392126.
  • Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–452.
  • Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from patients with pneumonia in China. N Engl J Med. 2019;382:727–733.
  • Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
  • Korean Society of Infectious D, Korean Society of Pediatric Infectious D, Korean Society of E, Korean Society for Antimicrobial T, Korean Society for Healthcare-associated Infection C, Prevention, Korea Centers for Disease C, Prevention. Report on the epidemiological features of Coronavirus Disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35:e112.
  • Mavragani A. Tracking COVID-19 in Europe: infodemiology approach. JMIR Public Health Surveill. 2020;6:e18941.
  • Steffens I. A hundred days into the coronavirus disease (COVID-19) pandemic. Euro Surveill. 2020;25: 2000550.
  • CDC COVID-19 Response Team. Geographic Differences in COVID-19 cases, deaths, and incidence - United States, February 12-April 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:465–471.
  • BBC. (22 December 2020 2020). Coronavirus spreads to Antarctic research station. https://www.bbc.com/news/world-latin-america-55410065. Accessed 17 January 2021.
  • World Health Organization. (2021). WHO Coronavirus Disease (COVID-19) Dashboard. Available at https://covid19.who.int./. Accessed 23 January 2021.
  • Chan JF, Lau SK, To KK, et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015;28:465–522.
  • Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
  • Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221–236.
  • Finkel Y, Mizrahi O, Nachshon A, et al. The coding capacity of SARS-CoV-2. Nature. 2021;589:125–130.
  • Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
  • Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448.
  • Suguitan AL J, Matsuoka Y, Lau YF, et al. The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals. J Virol. 2012;86:2706–2714.
  • Lau SY, Wang P, Mok BW, et al. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg Microbes Infect. 2020;9:837–842.
  • Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020;3: e202000786.
  • Mandala VS, McKay MJ, Shcherbakov AA, et al. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol. 2020;27:1202–1208.
  • Zheng Y, Zhuang MW, Han L, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduct Target Ther. 2020;5:299.
  • Peng Y, Du N, Lei Y, et al. Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. Embo j. 2020;39:e105938.
  • Ren Y, Shu T, Wu D, et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell Mol Immunol. 2020;17:881–883.
  • Yuen CK, Lam JY, Wong WM, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9:1418–1428.
  • Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–468.
  • Miorin L, Kehrer T, Sanchez-Aparicio MT, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci USA. 2020;117:28344–28354.
  • Gordon DE, Hiatt J, Bouhaddou M, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020;370: eabe9403.
  • Young BE, Fong SW, Chan YH, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020;396:603–611.
  • Lam JY, Yuen CK, Ip JD, et al. Loss of orf3b in the circulating SARS-CoV-2 strains. Emerg Microbes Infect. 2020;9:2685–2696.
  • Addetia A, Xie H, Roychoudhury P, et al. Identification of multiple large deletions in ORF7a resulting in in-frame gene fusions in clinical SARS-CoV-2 isolates. J Clin Virol. 2020;129:104523.
  • Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b Is a potent interferon antagonist whose activity Is increased by a naturally occurring elongation variant. Cell Rep. 2020;32:108185.
  • Jiang HW, Zhang HN, Meng QF, et al. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell Mol Immunol. 2020;17:998–1000.
  • Pancer K, Milewska A, Owczarek K, et al. The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans. PLoS Pathog. 2020;16:e1008959.
  • Schuster NA. Characterization and structural prediction of the putative ORF10 protein in SARS-CoV-2. bioRxiv. 2021. doi:https://doi.org/10.1101/2020.10.26.355784
  • Yeung ML. (2021). RNAi screening using HK-2 cells: insights into the roles of soluble ACE2 in SARS-CoV-2 infection. Mendeley Data 2.
  • Chu H, Hu B, Huang X, et al. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nat Commun. 2021;12:134.
  • Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370:861–865.
  • Cantuti-Castelvetri L,, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370:856–860.
  • Wang S, Qiu Z, Hou Y, et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 2021. doi:https://doi.org/10.1038/s41422-020-00460-y.
  • Wang K, Chen W, Zhang Z, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5:283.
  • Wei C, Wan L, Yan Q, et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nat Metab. 2020;2:1391–1400.
  • Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020;177:104759.
  • Wei J, Alfajaro MM, DeWeirdt PC, et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell. 2021;184:76–91. e13.
  • Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020. doi:https://doi.org/10.1038/s41579-020-00459-7.
  • Littler DR, Gully BS, Colson RN, et al. Crystal Structure of the SARS-CoV-2 Non-structural protein 9, Nsp9. iScience. 2020;23:101258.
  • Li J, Guo M, Tian X, et al. Virus-Host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. Med (N Y. 2021;2:99–112.e7.
  • Kim D, Lee JY, Yang JS, et al. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181:914–921.e10.
  • V'Kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020. doi:https://doi.org/10.1038/s41579-020-00468-6.
  • Lv H, Wu NC, Tsang OT, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;31:107725.
  • Manfredonia I, Nithin C, Ponce-Salvatierra A, et al. Genome-wide mapping of SARS-CoV-2 RNA structures identifies therapeutically-relevant elements. Nucleic Acids Res. 2020;48:12436–12452.
  • Hon CC, Lam TY, Shi ZL, et al. Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol. 2008;82:1819–1826.
  • Lam TT, Jia N, Zhang YW, et al. Identifying SARS-CoV-2-related coronaviruses in malayan pangolins. Nature. 2020;583:282–285.
  • Henry BM, Aggarwal G, Wong J, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38:1722–1726.
  • Boni MF, Lemey P, Jiang X, et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat Microbiol. 2020;5:1408–1417.
  • Day T, Gandon S, Lion S, et al. On the evolutionary epidemiology of SARS-CoV-2. Curr Biol. 2020;30:R849–R857.
  • Duchene S, Featherstone L, Haritopoulou-Sinanidou M, et al. Temporal signal and the phylodynamic threshold of SARS-CoV-2. Virus Evol. 2020;6:veaa061.
  • Laha S, Chakraborty J, Das S, et al. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol. 2020;85:104445.
  • Popa A, Genger JW, Nicholson MD, et al. Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Sci Transl Med. 2020;12: eabe2555.
  • Ip JD, Kok KH, Chan WM, et al. Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain. Clin Microbiol Infect. 2020. doi:https://doi.org/10.1016/j.cmi.2020.10.030.
  • Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5:1403–1407.
  • PANGO lineages. Global Report Investigating Novel Coronavirus Haplotypes. https://cov-lineages.org/global_report.html. Accessed 22 February.
  • To KK, Chan WM, Ip JD, et al. Unique SARS-CoV-2 clusters causing a large COVID-19 outbreak in Hong Kong. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1119.
  • Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284–1294 e9.
  • Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9: e61312.
  • Kemp SA, Collier DA, Datir R, et al. Neutralising antibodies drive spike mediated SARS-CoV-2 evasion. medRxiv. 2020. doi:https://doi.org/10.1101/2020.12.05.20241927
  • Martinot M, Jary A, Fafi-Kremer S, et al. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1474.
  • Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020;368:1016–1020.
  • Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2021;371:172–177.
  • Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369:1603–1607.
  • Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2-what do they mean? Jama. 2021;325:529–531.
  • Wong YC, Lau SY, To KK, et al. Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa953.
  • Wang X, Lam JY, Wong WM, et al. Accurate diagnosis of COVID-19 by a novel immunogenic secreted SARS-CoV-2 orf8 protein. mBio. 2020;11: e02431-20.
  • Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370:1464–1468.
  • Volz E, Hill V, McCrone JT, et al. Evaluating the effects of SARS-CoV-2 Spike Mutation D614G on transmissibility and pathogenicity. Cell. 2021;184:64–75 e11.
  • Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020. doi:https://doi.org/10.1038/s41586-020-2895-3.
  • Yurkovetskiy L, Wang X, Pascal KE, et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell. 2020;183:739–751 e8.
  • Koopmans M. SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. Lancet Infect Dis. 2021;21:18–19.
  • Davies N G, Barnard RC, Jarvis CI, et al. Estimated transmissibility and severity of novel SARS-CoV-2 variant of concern 202012/01 in england. MedRxiv. 2020. doi:https://doi.org/10.1101/2020122420248822.
  • Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.01.18.426984:2021.01.18.426984.
  • Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.01.18.427166
  • Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet. 2021. doi:https://doi.org/10.1016/S0140-6736(21)00183-5.
  • Control ECfDPa. (21 January 2021). Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update. https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf. Accessed 28 January 2021.
  • To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1275.
  • Vasques Nonaka CK, Miranda Franco M, Gräf T, et al. (2021). Genomic Evidence of a Sars-Cov-2 Reinfection Case With E484 K Spike Mutation in Brazil. Preprints 2021, 2021010132 (doi: https://doi.org/10.20944/preprints2021010132v1).
  • Jangra S, Ye C, Rathnasinghe R, et al. The E484 K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021. doi:https://doi.org/10.1101/2021.01.26.21250543
  • Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;71:2428–2446.
  • To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574.
  • Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020;323:1610–1612.
  • Chia PY, Coleman KK, Tan YK, et al. Singapore novel coronavirus outbreak research T. 2020. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. Nat Commun; 11:2800.
  • Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. Emerg Infect Dis. 2020;26:1583–1591.
  • Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature. 2020;582:557–560.
  • Lednicky JA, Lauzardo M, Fan ZH, et al. Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. Int J Infect Dis. 2020;100:476–482.
  • Asadi S, Wexler AS, Cappa CD, et al. Aerosol emission and superemission during human speech increase with voice loudness. Sci Rep. 2019;9:2348.
  • Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. Br Med J. 2020;369:m2094.
  • Cheng VC, Wong SC, Chan VW, et al. Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol. 2020;41:1258–1265.
  • Han J, Zhang X, He S, et al. Can the coronavirus disease be transmitted from food? A review of evidence, risks, policies and knowledge gaps. Environ Chem Lett. 2020. doi:https://doi.org/10.1007/s10311-020-01101-x:1-12.
  • Riddell S, Goldie S, Hill A, et al. The effect of temperature on persistence of SARS-CoV-2 on common surfaces. Virol J. 2020;17:145.
  • Morris DH, Yinda KC, Gamble A, et al. The effect of temperature and humidity on the stability of SARS-CoV-2 and other enveloped viruses. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.10.16.341883.
  • Xiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg Infect Dis. 2020;26:1920–1922.
  • Sun J, Zhu A, Li H, et al. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. Emerg Microbes Infect. 2020;9:991–993.
  • Colavita F, Lapa D, Carletti F, et al. SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection. Ann Intern Med. 2020;173:242–243.
  • Gross R, Conzelmann C, Muller JA, et al. Detection of SARS-CoV-2 in human breastmilk. Lancet. 2020;395:1757–1758.
  • Vivanti AJ, Vauloup-Fellous C, Prevot S, et al. Transplacental transmission of SARS-CoV-2 infection. Nat Commun. 2020;11:3572.
  • Lee AC, Zhang AJ, Chan JF, et al. Oral SARS-CoV-2 inoculation establishes subclinical respiratory infection with virus shedding in Golden Syrian hamsters. Cell Rep Med. 2020;1:100121.
  • Fenizia C, Biasin M, Cetin I, et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy. Nat Commun. 2020;11:5128.
  • Kang M, Wei J, Yuan J, et al. Probable evidence of Fecal aerosol transmission of SARS-CoV-2 in a high-rise building. Ann Intern Med. 2020;173:974–980.
  • Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
  • Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Int J Infect Dis. 2020;93:284–286.
  • Team CC-R. Geographic Differences in COVID-19 cases, deaths, and Incidence - United States, February 12-April 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:465–471.
  • Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395:689–697.
  • Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368:489–493.
  • Zhang Y, Li Y, Wang L, et al. Evaluating transmission heterogeneity and super-spreading event of COVID-19 in a metropolis of China. Int J Environ Res Public Health. 2020;17: 3705.
  • Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669–677.
  • Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship. Euro Surveill. 2020;25: 2000256.
  • Yamahata Y, Shibata A. Preparation for quarantine on the cruise ship Diamond Princess in Japan due to COVID-19. JMIR Public Health Surveill. 2020;6:e18821.
  • Yang R, Gui X, Xiong Y. Comparison of clinical Characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China. JAMA Netw Open. 2020;3:e2010182.
  • Chu H, Chan JF, Wang Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020;71:1400–1409.
  • Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–1772.
  • Slifka MK, Gao L. Is presymptomatic spread a major contributor to COVID-19 transmission? Nat Med. 2020;26:1531–1533.
  • He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26:672–675.
  • Ganyani T, Kremer C, Chen D, et al. Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. Euro Surveill. 2020;25: 2000257.
  • Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63:706–711.
  • Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infect Dis. 2021. doi:https://doi.org/10.1016/S1473-3099(20)30981-6.
  • Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26:1193–1195.
  • To KK, Cheng VC, Cai JP, et al. Seroprevalence of SARS-CoV-2 in Hong Kong Special Administrative Region and our returnees evacuated from Hubei province of China: a multi-cohort study. Lancet Microbe. 2020. doi:https://doi.org/10.1016/S2666-5247(20)30053-7.
  • Liu A, Li Y, Wan Z, et al. Seropositive prevalence of antibodies against SARS-CoV-2 in Wuhan, China. JAMA Netw Open. 2020;3:e2025717.
  • Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-specific antibodies Among adults in Los Angeles county, california, on April 10–11, 2020. JAMA. 2020;323:2425–2427.
  • To KKW, Yuen KY. Responding to COVID-19 in Hong Kong. Hong Kong Med J. 2020;26:164–166.
  • Li X, Sridhar S, Chan JF. The coronavirus disease 2019 pandemic: how does it spread and how do we stop it? Curr Opin HIV AIDS. 2020;15:328–335.
  • Hodcroft EB. Preliminary case report on the SARS-CoV-2 cluster in the UK, France, and Spain. Swiss Med Wkly. 2020;150(9–10). doi:https://doi.org/10.4414/smw.2020.20212.
  • Kim S, Jeong YD, Byun JH, et al. Evaluation of COVID-19 epidemic outbreak caused by temporal contact-increase in South Korea. Int J Infect Dis. 2020;96:454–457.
  • Kang J, Jang YY, Kim J, et al. South Korea's responses to stop the COVID-19 pandemic. Am J Infect Control. 2020;48:1080–1086.
  • Chang S, Pierson E, Koh PW, et al. Mobility network models of COVID-19 explain inequities and inform reopening. Nature. 2021;589:82–87.
  • Jung J, Hong MJ, Kim EO, et al. Investigation of a nosocomial outbreak of coronavirus disease 2019 in a paediatric ward in South Korea: successful control by early detection and extensive contact tracing with testing. Clin Microbiol Infect. 2020;26:1574–1575.
  • Schwierzeck V, König JC, Kühn J, et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa491.
  • Zhang BZ, Chu H, Han S, et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020;30:928–931.
  • Zhang AJ, Lee AC, Chu H, et al. SARS-CoV-2 infects and damages the mature and immature olfactory sensory neurons of hamsters. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa995.
  • Zhou J, Li C, Liu X, et al. Infection of bat and human intestinal organoids by SARS-CoV-2. Nat Med. 2020;26:1077–1083.
  • Chu H, Chan JF, Yuen TT, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020;1:e14–e23.
  • Bradley BT, Maioli H, Johnston R, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington state: a case series. Lancet. 2020;396:320–332.
  • Bois MC, Boire NA, Layman AJ, et al. COVID-19-Associated nonocclusive fibrin microthrombi in the heart. Circulation. 2021;143:230–243.
  • Deshmukh V, Motwani R, Kumar A, et al. Histopathological observations in COVID-19: a systematic review. J Clin Pathol. 2021;74:76–83.
  • Stonoga ETS, de Almeida Lanzoni L, Rebutini PZ, et al. Intrauterine transmission of SARS-CoV-2. Emerg Infect Dis. 2021;27:638–641.
  • Yang M, Chen S, Huang B, et al. Pathological findings in the testes of COVID-19 patients: clinical implications. Eur Urol Focus. 2020;6:1124–1129.
  • Chu H, Chan JF, Wang Y, et al. SARS-CoV-2 Induces a more Robust innate immune response and replicates less efficiently than SARS-CoV in the human intestines: An Ex Vivo Study With Implications on pathogenesis of COVID-19. Cell Mol Gastroenterol Hepatol. 2020;11:771–781.
  • Zhang AJ, Lee AC, Chan JF, et al. Co-infection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1747.
  • Ye ZW, Yuan S, Chan JF, et al. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Emerg Microbes Infect. 2021. doi:https://doi.org/10.1080/22221751.2021.1885998:1-38.
  • Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8:681–686.
  • Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and Angiogenesis in covid-19. N Engl J Med. 2020;383:120–128.
  • Hariri LP, North CM, Shih AR, et al. Lung Histopathology in Coronavirus Disease 2019 as compared With severe acute respiratory sydrome and H1N1 influenza: A systematic review. Chest. 2021;159:73–84.
  • Garvin MR, Alvarez C, Miller JI, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020;9: e59177.
  • Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. medRxiv. 2020. doi:https://doi.org/10.1101/2020.12.10.20247205.
  • Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370: eabd4585.
  • Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418.
  • Smadja DM, Guerin CL, Chocron R, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;23:611–620.
  • Maharaj S, Xue R, Rojan A. Thrombotic thrombocytopenic purpura (TTP) response following COVID-19 infection: implications for the ADAMTS13-von Willebrand factor axis. J Thromb Haemost. 2020. doi:https://doi.org/10.1111/jth.15230.
  • Gasecka A, Borovac JA, Guerreiro RA, et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2020. doi:https://doi.org/10.1007/s10557-020-07084-9.
  • Pujhari S, Paul S, Ahluwalia J, et al. Clotting disorder in severe acute respiratory syndrome coronavirus 2. Rev Med Virol. 2020. doi:https://doi.org/10.1002/rmv.2177:e2177.
  • Occidental M, Flaifel A, Lin LH, et al. Investigating the spectrum of dermatologic manifestations in COVID-19 infection in severely ill patients: A series of four cases. J Cutan Pathol. 2021;48:110–115.
  • Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1–13.
  • Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020. doi:https://doi.org/10.1016/j.kint.2020.05.013.
  • Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142:1176–1189.
  • Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169–1179.
  • Schurink B, Roos E, Radonic T, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1:e290–e299.
  • Imazio M, Klingel K, Kindermann I, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Heart. 2020. doi:https://doi.org/10.1136/heartjnl-2020-317186.
  • Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1:e245–e253.
  • Liu Q, Shi Y, Cai J, et al. Pathological changes in the lungs and lymphatic organs of 12 COVID-19 autopsy cases. Natl Sci Rev. 2020;7:1868–1878.
  • Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2020. doi:https://doi.org/10.1038/s41593-020-00771-8.
  • Solomon T. Neurological infection with SARS-CoV-2 - the story so far. Nat Rev Neurol. 2021. doi:https://doi.org/10.1038/s41582-020-00453-w.
  • Al-Sarraj S, Troakes C, Hanley B, et al. Invited review: The spectrum of neuropathology in COVID-19. Neuropathol Appl Neurobiol. 2020. doi:https://doi.org/10.1111/nan.12667.
  • Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218: e20202135.
  • Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919–929.
  • Kirschenbaum D, Imbach LL, Ulrich S, et al. Inflammatory olfactory neuropathy in two patients with COVID-19. Lancet. 2020;396:166.
  • Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med. 2020;383:989–992.
  • von Weyhern CH, Kaufmann I, Neff F, et al. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020;395:e109.
  • Puelles VG, Lutgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383:590–592.
  • Keller E, Brandi G, Winklhofer S, et al. Large and small cerebral vessel involvement in severe COVID-19: detailed clinical workup of a case series. Stroke. 2020;51:3719–3722.
  • Pugin D, Vargas MI, Thieffry C, et al. COVID-19-related encephalopathy responsive to high-dose glucocorticoids. Neurology. 2020;95:543–546.
  • Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2020. doi:https://doi.org/10.1038/s41593-020-00758-5.
  • Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6.
  • Shuai H, Chu H, Hou Y, et al. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-beta and IFN inducer. J Infect. 2020;81:e1–e10.
  • Yang D, Chu H, Hou Y, et al. Attenuated interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells Is Associated With viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020;222:734–745.
  • Lei X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11:3810.
  • Zhou R, To KK, Wong YC, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53:864–877.e5.
  • Jimenez F, Quinones MP, Martinez HG, et al. CCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 and NF-kappa B. J Immunol. 2010;184:5571–5581.
  • Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034.
  • Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–469.
  • Jiang HW, Li Y, Zhang HN, et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020;11:3581.
  • Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971–977 e3.
  • Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396:1595–1606.
  • Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5: eabe5511.
  • Liu L, To KK, Chan KH, et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microbes Infect. 2020;9:1664–1670.
  • Chen Y, Zuiani A, Fischinger S, et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell. 2020;183:1496–1507. e16.
  • Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227–1230.
  • Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063.
  • Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22:25–31.
  • Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383:1724–1734.
  • To KK-W, Hung IF-N, Chan K-H, et al. Serum antibody profile of a patient with Coronavirus disease 2019 reinfection. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1368.
  • De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11:3434.
  • Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221:1762–1769.
  • Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e19.
  • Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501. e15.
  • Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
  • Zhang J, Wu Q, Liu Z, et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat Microbiol. 2021;6:51–58.
  • Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462.
  • Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587:270–274.
  • Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370:89–94.
  • Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. Br Med J. 2020;369:m1985.
  • Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–2059.
  • Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:759–765.
  • Chung TW, Sridhar S, Zhang AJ, et al. Olfactory Dysfunction in Coronavirus Disease 2019 patients: observational cohort study and systematic review. Open Forum Infect Dis. 2020;7:ofaa199.
  • Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574–2576.
  • Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334–346.
  • Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab. 2021;106:e926–e935.
  • Wu Z, McGoogan JM. Characteristics of and important Lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323:1239–1242.
  • Aguilar RB, Hardigan P, Mayi B, et al. Current understanding of COVID-19 clinical course and investigational treatments. Front Med (Lausanne). 2020;7:555301.
  • Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71:2027–2034.
  • Gandhi RT, Lynch JB, Del Rio C. Mild or moderate covid-19. N Engl J Med. 2020;383:1757–1766.
  • Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81:357–371.
  • Yuan S, Chan JFW, Chik KKH, et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and Abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol Res. 2020;159:104960.
  • Chan JCX, Kwok KY, Ma JKF, et al. Radiology and COVID-19. Hong Kong Med J. 2020;26:286–288.
  • Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Br Med J. 2020;369:m1966.
  • Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in covid-19. Nature. 2020. doi:https://doi.org/10.1038/s41586-020-03065-y.
  • The Severe Covid-19 GWAS Group. Genomewide Association study of severe covid-19 with respiratory failure. N Engl J Med. 2020;383:1522–1534.
  • Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.
  • Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570.
  • van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324:663–673.
  • Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality Initiative (ADQI) workgroup. Nature Reviews Nephrology. 2020;16:747–764.
  • Cao Y, Hiyoshi A, Montgomery S. COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data. BMJ Open. 2020;10:e043560.
  • World Health Organization. (2020). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed on 23rd January 2021.
  • Salmanton-García J, Sprute R, Stemler J, et al. COVID-19-associated pulmonary aspergillosis, March-August 2020. Emerg Infect Dis. 2021;27. doi:https://doi.org/10.3201/eid2704.204895.
  • Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232.
  • Baig AM. Chronic COVID Syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol. 2020. doi:https://doi.org/10.1002/jmv.26624.
  • Baig AM. Deleterious outcomes in Long-Hauler COVID-19: The effects of SARS-CoV-2 on the CNS in Chronic COVID syndrome. ACS Chem Neurosci. 2020;11:4017–4020.
  • Greenhalgh T, Knight M, A'Court C, et al. Management of post-acute covid-19 in primary care. Br Med J. 2020;370:m3026.
  • Mizrahi B, Shilo S, Rossman H, et al. Longitudinal symptom dynamics of COVID-19 infection. Nat Commun. 2020;11:6208.
  • Chua GT, Xiong X, Choi EH, et al. COVID-19 in children across three Asian cosmopolitan regions. Emerg Microbes Infect. 2020;9:2588–2596.
  • Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334–346.
  • Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183:968–981. e7.
  • Ji T, Liu Z, Wang G, et al. Detection of COVID-19: A review of the current literature and future perspectives. Biosens Bioelectron. 2020;166:112455.
  • Ejazi SA, Ghosh S, Ali N. Antibody detection assays for COVID-19 diagnosis: an early overview. Immunol Cell Biol. 2021;99:21–33.
  • World Health Organization. (11th September 2020). Interim Guidance on Diagnostic Testing for SARS-CoV-2.
  • Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–1844.
  • To KK, Tsang OT, Yip CC, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020;71:841–843.
  • To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin Microbiol Infect. 2019;25:372–378.
  • Chen JH, Yip CC, Poon RW, et al. Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. Emerg Microbes Infect. 2020;9:1356–1359.
  • Braz-Silva PH, Mamana AC, Romano CM, et al. Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19. J Oral Microbiol. 2020;13:1858002.
  • Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020;383:1283–1286.
  • Wong SCY, Tse H, Siu HK, et al. Posterior oropharyngeal saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:2939–2946.
  • Hung DL, Li X, Chiu KH, et al. Early-Morning vs spot posterior oropharyngeal saliva for diagnosis of SARS-CoV-2 infection: Implication of timing of specimen collection for community-wide screening. Open Forum Infect Dis. 2020;7:ofaa210.
  • Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2011335.
  • Larsen DA, Wigginton KR. Tracking COVID-19 with wastewater. Nat Biotechnol. 2020;38:1151–1153.
  • Hamouda M, Mustafa F, Maraqa M, et al. Wastewater surveillance for SARS-CoV-2: Lessons learnt from recent studies to define future applications. Sci Total Environ. 2021;759:143493.
  • Matrajt G, Naughton B, Bandyopadhyay AS, et al. A review of the most commonly used methods for sample collection in environmental surveillance of poliovirus. Clin Infect Dis. 2018;67:S90–S97.
  • Li X, Chan JF, Li KK, et al. Detection of SARS-CoV-2 in conjunctival secretions from patients without ocular symptoms. Infection. 2020. doi:https://doi.org/10.1007/s15010-020-01524-2.
  • Lohse S, Pfuhl T, Berko-Gottel B, et al. Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis. 2020;20:1231–1232.
  • Torres I, Albert E, Navarro D. Pooling of nasopharyngeal swab specimens for SARS-CoV-2 detection by RT-PCR. J Med Virol. 2020;92:2306–2307.
  • Griesemer SB, Van Slyke G, St George K. Assessment of sample pooling for clinical SARS-CoV-2 testing. J Clin Microbiol. 2021. doi:https://doi.org/10.1128/JCM.01261-20.
  • Tan JG, Omar A, Lee WB, et al. Considerations for group testing: A practical approach for the clinical laboratory. Clin Biochem Rev. 2020;41:79–92.
  • Mutesa L, Ndishimye P, Butera Y, et al. A pooled testing strategy for identifying SARS-CoV-2 at low prevalence. Nature. 2021;589:276–280.
  • Fernandez-Salinas J, Aragon-Caqueo D, Valdes G, et al. Modelling pool testing for SARS-CoV-2: addressing heterogeneity in populations. Epidemiol Infect. 2020;149:e9.
  • Tang YW, Schmitz JE, Persing DH, et al. Laboratory diagnosis of COVID-19: current issues and challenges. J Clin Microbiol. 2020;58(6): e00512-20.
  • Chan JF, Yip CC, To KK, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time Reverse transcription-PCR assay validated In vitro and with clinical specimens. J Clin Microbiol. 2020;58(5): e00310-20.
  • Mahase E. Covid-19: sore throat, fatigue, and myalgia are more common with new UK variant. Br Med J. 2021;372:n288.
  • Broughton JP, Deng X, Yu G, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38:870–874.
  • Zeng W, Liu G, Ma H, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527:618–623.
  • Lambert-Niclot S, Cuffel A, Le Pape S, et al. Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs. J Clin Microbiol. 2020;58(8): e00977-20.
  • Krammer F, Simon V. Serology assays to manage COVID-19. Science. 2020;368:1060–1061.
  • Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2020. doi:https://doi.org/10.1136/bmjebm-2020-111511.
  • Fong CH, Cai JP, Dissanayake TK, et al. Improved detection of antibodies against SARS-CoV-2 by microsphere-based antibody assay. Int J Mol Sci. 2020;21(18): 6595.
  • OM E, Byrne P, Walsh KA, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review. Rev Med Virol. 2020. doi:https://doi.org/10.1002/rmv.2162:e2162
  • Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–1204.
  • Shu H, Wang S, Ruan S, et al. Dynamic changes of antibodies to SARS-CoV-2 in COVID-19 patients at early stage of outbreak. Virol Sin. 2020;35:744–751.
  • Van Elslande J, Decru B, Jonckheere S, et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect. 2020;26:1557.e1–1557.e7.
  • Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–686.
  • Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol. 2020;38:1073–1078.
  • Chia WN, Tan CW, Foo R, et al. Serological differentiation between COVID-19 and SARS infections. Emerg Microbes Infect. 2020;9:1497–1505.
  • Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370 (6520): eabd4250.
  • Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469.
  • Apolone G, Montomoli E, Manenti A, et al. Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. Tumori. 2020. doi:https://doi.org/10.1177/0300891620974755:300891620974755.
  • Basavaraju SV, Patton ME, Grimm K, et al. Serologic testing of US blood donations to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–reactive antibodies: December 2019–January 2020. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1785.
  • Stelzer-Braid S, Walker GJ, Aggarwal A, et al. Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. Pathology. 2020;52:760–763.
  • Walsh KA, Spillane S, Comber L, et al. The duration of infectiousness of individuals infected with SARS-CoV-2. J Infect. 2020;81:847–856.
  • Byrne AW, McEvoy D, Collins AB, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open. 2020;10:e039856.
  • van Kampen JJA, van de Vijver D, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun. 2021;12:267.
  • Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020;117:7001–7003.
  • Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021. doi:https://doi.org/10.1038/s41586-021-03237-4.
  • Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020;383:1827–1837.
  • Consortium WHOST, Pan H, Peto R, et al. Repurposed antiviral drugs for covid-19 - interim WHO Solidarity trial results. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2023184.
  • Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704.
  • Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020. doi:https://doi.org/10.1016/S2213-2600(20)30511-7.
  • Yuan S, Chan CC, Chik KK, et al. Broad-Spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19). Viruses. 2020;12. doi:https://doi.org/10.3390/v12060628.
  • Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384:238–251.
  • Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in Outpatients with covid-19. N Engl J Med. 2021;384:229–237.
  • Group A-TL-CS, Lundgren JD, Grund B, et al. A neutralizing monoclonal antibody for hospitalized patients with covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2033130.
  • Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2031304.
  • Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119.
  • Yuan S, Wang R, Chan JF, et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020;5:1439–1448.
  • Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19 - Preliminary report. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2021436.
  • Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. Jama. 2020;324:1330–1341.
  • Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2031994.
  • Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;384:20–30.
  • Gupta S, Wang W, Hayek SS, et al. Association between early treatment With tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181:41–51.
  • Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. Br Med J. 2021;372:n84.
  • Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA. 2020;324:2292–2300.
  • Cheng LL, Guan WJ, Duan CY, et al. Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: A randomized clinical trial. JAMA Intern Med. 2021;181:71–78.
  • Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8:518–526.
  • Shakya KM, Noyes A, Kallin R, et al. Evaluating the efficacy of cloth facemasks in reducing particulate matter exposure. J Expo Sci Environ Epidemiol. 2017;27:352–357.
  • Kim MC, Bae S, Kim JY, et al. Effectiveness of surgical, KF94, and N95 respirator masks in blocking SARS-CoV-2: a controlled comparison in 7 patients. Infect Dis (Lond). 2020;52:908–912.
  • Chan TK. Universal masking for COVID-19: evidence, ethics and recommendations. BMJ Glob Health. 2020;5: e002819.
  • IMHE COVID-19 Forecasting Team. Modeling COVID-19 scenarios for the United States. Nat Med. 2021;27:94–105.
  • Meyerowitz EA, Richterman A, Bogoch II, et al. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infect Dis. doi:https://doi.org/10.1016/S1473-3099(20)30837-9.
  • Almagor J, Picascia S. Exploring the effectiveness of a COVID-19 contact tracing app using an agent-based model. Sci Rep. 2020;10:22235.
  • Cheng VCC, Wong SC, Chuang VWM, et al. Absence of nosocomial transmission of coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in the prepandemic phase in Hong Kong. Am J Infect Control. 2020;48:890–896.
  • Cheng VCC, Wong SC, Wong SCY, et al. Directly observed hand hygiene - from healthcare workers to patients. J Hosp Infect. 2019;101:380–382.
  • Wong SC, AuYeung CH, Lam GK, et al. Is it possible to achieve 100 percent hand hygiene compliance during the coronavirus disease 2019 (COVID-19) pandemic? J Hosp Infect. 2020;105:779–781.
  • Cheng VCC, Wong SC, Chen JHK, et al. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol. 2020;41:493–498.
  • Cheng VC, Chan JF, To KK, et al. Clinical management and infection control of SARS: lessons learned. Antiviral Res. 2013;100:407–419.
  • Haymet A, Bassi GL, Fraser JF. Airborne spread of SARS-CoV-2 while using high-flow nasal cannula oxygen therapy: myth or reality? Intensive Care Med. 2020;46:2248–2251.
  • Klompas M, Morris CA, Sinclair J, et al. Universal masking in hospitals in the covid-19 Era. N Engl J Med. 2020;382:e63.
  • Wong SC, Lam GK, AuYeung CH, et al. Absence of nosocomial influenza and respiratory syncytial virus infection in the coronavirus disease 2019 (COVID-19) era: Implication of universal masking in hospitals. Infect Control Hosp Epidemiol. 2020. doi:https://doi.org/10.1017/ice.2020.425:1-4.
  • Cheng VC, Wong SC, Chuang VW, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. J Infect. 2020;81:107–114.
  • Chen S, Zhang Z, Yang J, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. Lancet. 2020;395:1305–1314.
  • Wong SC, Leung M, Tong DW, et al. Infection control challenges in setting up community isolation and treatment facilities for patients with coronavirus disease 2019 (COVID-19): implementation of directly-observed environmental disinfection. Infect Control Hosp Epidemiol. 2020. doi:https://doi.org/10.1017/ice.2020.1355:1-29.
  • Chia ML, Him Chau DH, Lim KS, et al. Managing COVID-19 in a novel, rapidly deployable community isolation quarantine facility. Ann Intern Med. 2020. doi:https://doi.org/10.7326/m20-4746.
  • World Health Organisation. (29 July 2020). Ventilation and air conditioning in health facilities and COVID-19. https://www.who.int/news-room/q-a-detail/q-a-ventilation-and-air-conditioning-in-health-facilities-and-covid-19. Accessed.
  • Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. Br Med J. 2020;369:m2195.
  • World Health Organisation. (2020). COVID-19 Technical Specifications for personal protective equipment, list of standards and checklists. https://www.who.int/publications/m/item/technical-specs-PPE-Covid19-07082020. Accessed 29 January.
  • Ranney ML, Griffeth V, Jha AK. Critical supply shortages - The need for ventilators and personal protective equipment during the covid-19 pandemic. N Engl J Med. 2020;382:e41.
  • Lynch JB, Davitkov P, Anderson DJ, et al. Infectious Diseases Society of America guidelines on infection Prevention for health care personnel caring for patients with suspected or known COVID-19. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1063.
  • Wong SC, Leung M, Lee LL, et al. Infection control challenge in setting up a temporary test centre at Hong Kong international airport for rapid diagnosis of COVID-19 due to SARS-CoV-2. J Hosp Infect. 2020;105:571–573.
  • Foong TW, Hui Ng ES, Wee Khoo CY, et al. Rapid training of healthcare staff for protected cardiopulmonary resuscitation in the COVID-19 pandemic. Br J Anaesth. 2020;125:e257–e259.
  • Hul V, Delaune D, Karlsson EA, et al. A novel SARS-CoV-2 related coronavirus in bats from Cambodia. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.01.26.428212.
  • Wacharapluesadee S, Tan CW, Maneeorn P, et al. Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nat Commun. 2021;12:972.
  • Murakami S, Kitamura T, Suzuki J, et al. Detection and Characterization of Bat Sarbecovirus phylogenetically related to SARS-CoV-2, Japan. Emerg Infect Dis. 2020;26:3025–3029.
  • Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in domestic cats. N Engl J Med. 2020;383:592–594.
  • Sit THC, Brackman CJ, Ip SM, et al. Infection of dogs with SARS-CoV-2. Nature. 2020;586:776–778.
  • McAloose D, Laverack M, Wang L, et al. From people to panthera: natural SARS-CoV-2 infection in tigers and lions at the Bronx Zoo. mBio. 2020;11: e02220-20.
  • Conceicao C, Thakur N, Human S, et al. The SARS-CoV-2 spike protein has a broad tropism for mammalian ACE2 proteins. PLoS Biol. 2020;18:e3001016.
  • Muñoz-Fontela C, Dowling WE, Funnell SGP, et al. Animal models for COVID-19. Nature. 2020;586:509–515.
  • Chan JF, Yuan S, Zhang AJ, et al. Surgical mask partition reduces the risk of noncontact transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020;71:2139–2149.
  • Kim YI, Kim SG, Kim SM, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 2020;27:704–709.e2.
  • Richard M, Kok A, de Meulder D, et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun. 2020;11:3496.
  • Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21:1327–1335.
  • Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583:830–833.
  • Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28:124–133. e4.
  • Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182:744–753.e4.
  • Rathnasinghe R, Strohmeier S, Amanat F, et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020;9:2433–2445.
  • Mykytyn AZ, Lamers MM, Okba NMA, et al. Susceptibility of rabbits to SARS-CoV-2. Emerg Microbes Infect. 2021;10:1–7.
  • Schlottau K, Rissmann M, Graaf A, et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe. 2020;1:e218–e225.
  • Berhane Y, Suderman M, Babiuk S, Pickering B. Susceptibility of turkeys, chickens and chicken embryos to SARS-CoV-2. Transbound Emerg Dis. 2020 Dec 29. doi:https://doi.org/10.1111/tbed.13970.
  • Cross RW, Agans KN, Prasad AN, et al. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase. Virol J. 2020;17:125.
  • Singh DK, Singh B, Ganatra SR, et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat Microbiol. 2021;6:73–86.
  • Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450.
  • FDA. (2020). Vacccines and Related Biological Products Advisory Committee Meeting. https://www.fda.gov/media/144245/download. Accessed 29 January.
  • Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
  • Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. doi:https://doi.org/10.1016/S0140-6736(21)00234-8.
  • MaCC V, Ann S, Madhi SA, et al. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine. Lancet. 2021;397:881–891.
  • Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020;21:181–192.
  • Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51.
  • Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–2332.
  • Huang B, Dai L, Wang H, et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.02.01.429069.
  • Wang P, Liu L, Iketani S, et al. Increased Resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.01.25.428137
  • Li C, Chen YX, Liu FF, et al. Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model. Clin Infect Dis. 2021. doi:https://doi.org/10.1093/cid/ciab083.
  • Cheng VC, Lau SK, Woo PC, et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20:660–694.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.